Astellas Announces Completion of Acquisition of Own Shares, and Cancellation of Treasury Stock

- Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act -

TOKYO, March 16, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the status and the completion of acquisition of its own shares based on the resolution of the Board of Directors’ meeting held on February 6, 2023, pursuant to the Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

The Company also announced the number of shares to be canceled on March 29, 2023 pursuant to Article 178 of the Companies Act has been finalized.

Particulars

1. Status of acquisition of own shares

(1) Class of shares acquired: Common stock of the Company
(2) Total number of shares acquired: 11,034,900 shares
(3) Total amount of acquisition cost: 20,976,410,700 yen
(4) Period of acquisition: From March 1, 2023 to March 15, 2023
(5) Method of acquisition: Market purchase on the Tokyo Stock Exchange

2. Details of the cancellation of treasury stock

(1) Class of shares to be cancelled: Common stock of the Company
(2) Number of shares to be cancelled: 26,188,500 shares
   (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.44%)
(3) Cancellation date: March 29, 2023
(Reference)

1. Details of the resolution at the meeting of the Board of Directors on February 6, 2023

(1) Class of shares to be acquired: Common stock of the Company

(2) Total number of shares to be acquired: Up to 29 million shares
   (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)

(3) Total amount of acquisition cost: Up to 50 billion yen

(4) Period of acquisition: From February 7, 2023 to March 24, 2023

(5) Method of acquisition: Market purchase on the Tokyo Stock Exchange

2. Accumulated Company’s own shares acquired pursuant to the above board resolution

(1) Total number of shares acquired: 26,188,500 shares
   (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.44%)

(2) Total amount of acquisition cost: 49,999,962,150 yen

3. Details of the decided cancellation of treasury stock (February 6, 2023)

(1) Class of shares to be cancelled: Common stock of the Company

(2) Total number of shares to be cancelled:
   All of the shares repurchased as stated in 2 above

(3) Scheduled cancellation date: March 29, 2023
4. Status of shares after cancellation

(1) Number of shares issued: 1,809,663,075 shares (expected)

(2) Number of the Company’s treasury stock: 13,008,595 shares (expected)

[Estimated numbers of shares described above (1) and (2) were calculated on the basis of the issued shares and the Company’s treasury stock as of February 28, 2023, respectively.]

About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
+81-3-3244-3201